Overcoming Barriers in Glioblastoma—Advances in Drug Delivery Strategies

Author:

ter Linden Esther1,Abels Erik R.1ORCID,van Solinge Thomas S.2,Neefjes Jacques1,Broekman Marike L. D.123

Affiliation:

1. Department of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, 2300 RC Leiden, The Netherlands

2. Department of Neurosurgery, Leiden University Medical Center, 2300 RC Leiden, The Netherlands

3. Department of Neurosurgery, Haaglanden Medical Center, 2512 VA The Hague, The Netherlands

Abstract

The world of cancer treatment is evolving rapidly and has improved the prospects of many cancer patients. Yet, there are still many cancers where treatment prospects have not (or hardly) improved. Glioblastoma is the most common malignant primary brain tumor, and even though it is sensitive to many chemotherapeutics when tested under laboratory conditions, its clinical prospects are still very poor. The blood–brain barrier (BBB) is considered at least partly responsible for the high failure rate of many promising treatment strategies. We describe the workings of the BBB during healthy conditions and within the glioblastoma environment. How the BBB acts as a barrier for therapeutic options is described as well as various approaches developed and tested for passing or opening the BBB, with the ultimate aim to allow access to brain tumors and improve patient perspectives.

Funder

Dutch Cancer Society

Hersenstichting

Spinza grand by the Institute for Chemical Immunology

Publisher

MDPI AG

Reference143 articles.

1. Impact of extent of resection for recurrent glioblastoma on overall survival: Clinical article;Bloch;J. Neurosurg.,2012

2. Primary brain tumours in adults;Geurts;Lancet,2023

3. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019;Ostrom;Neuro Oncol.,2022

4. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N. Engl. J. Med.,2005

5. Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: To whom do the results of the trials apply?;Skaga;Neurooncol. Adv.,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3